EGFR and melanoma: Co-administration with gefitinib, linsitinib and GW5074 could achieve the most significant inhibition of cell proliferation in VemR A375 cells (cell proliferation suppressed by 81%, p < 0.0001) (Figure 3F), indicating that co-inhibition of EGFR/IGF-1R/CRAF could markedly decrease VemR melanoma cell proliferation.